RA CAPITAL MANAGEMENT L.P. 13D/13G Filings for Keros Therapeutics, Inc. (KROS)

RA CAPITAL MANAGEMENT L.P. 13D and 13G filings for Keros Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		Transaction
Date		TypeCompany
Symbol		Filed By
Symbol		Shares Owned
% Owned		Shares Vs. Prev ReportView
2021-02-10
4:48 pm
Sale		2021-01-3113GKeros Therapeutics, Inc.
KROS		RA CAPITAL MANAGEMENT L.P.0
0.000%		-1,875,000decrease
(Position Closed)		Filing
2021-02-10
4:31 pm
Purchase		2020-12-3113GKeros Therapeutics, Inc.
KROS		RA CAPITAL MANAGEMENT L.P.1,875,000
8.100%		1,875,000increase
(New Position)		Filing